Free tool
FAERS Monitor: Infuvite Pediatric (Pharmacy Bulk Package)
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021265 or its brand name (Infuvite Pediatric (Pharmacy Bulk Package), Ascorbic Acid, Biotin, Cholecalciferol, Cyanocobalamin, Dexpanthenol, Folic Acid, Niacinamide, Pyridoxine, Riboflavin, Thiamine, Tocopherol Acetate, Vitamin A, Vitamin K). Reports on generic versions are filed under their own applications.
Reports
24
Serious
14
58% of reports
Hospitalization
2
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea4
- cough3
- erythema3
- rash generalised3
- tachycardia3
- vomiting3
- anaphylactic reaction2
- chest discomfort2
- grunting2
- hypersensitivity2
- medication error2
- paraesthesia2
- product dispensing error2
- rash2
- rash erythematous2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 1 |
| 2016 | 5 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,135 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| grunting | 2 | 2938.9 | 777.8 | 3,292 |
| rash generalisedSignal | 3 | 101.6 | 35.2 | 207 |
| product dispensing error | 2 | 80.5 | 21.4 | 88 |
| rash erythematous | 2 | 36.7 | 9.7 | 38 |
| anaphylactic reaction | 2 | 31.7 | 8.4 | 33 |
| medication error | 2 | 31.5 | 8.4 | 33 |
| tachycardiaSignal | 3 | 29.6 | 10.3 | 57 |
| chest discomfort | 2 | 17.1 | 4.5 | 16 |
| erythemaSignal | 3 | 12.8 | 4.4 | 22 |
| paraesthesia | 2 | 11.1 | 3.0 | 10 |
| hypersensitivity | 2 | 9.4 | 2.5 | 8 |
| coughSignal | 3 | 9.4 | 3.3 | 15 |
| dyspnoeaSignal | 4 | 6.2 | 2.5 | 13 |
| vomitingSignal | 3 | 5.6 | 1.9 | 7 |
| rash | 2 | 4.0 | 1.1 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.